Summary

Closed System Drug Transfer Device Market Research Report Information By type (Membrane to Membrane and Needleless System), By Component (Vial Access Devices, Syringe Safety Devices, Accessories, Bag/Line Access Devices), By Closing Mechanism (Push to Turn System, Color-to-color Alignment System, Leur Lock Systems, Click to Lock Systems), By Technology (Compartmentalize Devices, Diaphragm-Based Devices, and Air Filtration Devices) By Region- Forecast to 2032

Market Overview
The market for Closed System Drug Transfer Devices was estimated to be worth USD 1.07 billion by 2023. The market is expected to increase from USD 1.20 billion in 2024 to USD 2.87 billion by 2032, with a compound annual growth rate (CAGR) of 10.17% for the forecast period (2024-2032). The rising incidence of cancer worldwide, combined with tight regulatory requirements in the healthcare industry, is propelling market expansion.
The rising incidence of cancer around the world is driving the global closed-system drug transfer device (CSTD) market. This is because cancer treatment frequently necessitates the use of toxic medications, which can be dangerous to healthcare professionals. The device creates a closed and leak-proof system to aid in the escape of these hazardous substances into the environment. Furthermore, the cancer burden is increasing globally as a result of reasons such as an aging population, environmental variables, improved diagnostic capabilities, and lifestyle changes, all of which are driving market expansion.
Marketing Segmentation
The global closed-system drug transfer device market is divided into two types: membrane-to-membrane systems and unnecessary systems.
The market is divided into four components: vial access devices, syringe safety devices, bag/line access devices, and accessories.
The market is divided into push-to-turn systems, color-to-color alignment systems, leur lock systems, and click-to lock systems according on the closing mechanism.
The Closed System Drug Transfer Device Market is divided into three technology segments: compartmentalized devices, diaphragm-based devices, and air filtration devices.
The market is split by end user, including hospitals, clinics, specialized centers, and others.
Regional insights
The Closed System Drug Transfer Device Market has been classified by region: North America, Europe, Asia-Pacific, and the Rest of the World. North America held the highest market share in 2023 and is expected to reach USD 9.92 billion by 2032, with a CAGR of 9.10% over the forecast period.
North America has the greatest market share of 38.14% and is expected to lead the global CSTD market. This huge market share is attributed to the rising number of cancer cases and the robust research and development infrastructure. For example, in 2020, the United States reported 1,603,844 new cancer cases and 602,347 cancer deaths.
Asia-Pacific is likely to have considerable growth and will be the fastest growing region over the projection period, owing to the increasing number of new vendors active in the drug-device system, as many regional/small market participants attempt to gain market share.
The Closed System Drug Transfer Device Market is distinguished by the presence of numerous global, regional, and domestic vendors. The market is extremely competitive, with all firms vying for the highest market share. Intense rivalry and frequent changes in government rules and regulations are major factors influencing market growth.
Major Players
Becton, Dickson, and Company, Inc., Baxter International Inc., ICU Medical, Inc., JMS Co.Ltd, B. Braun SE, Simplivia (Israel), Becton, Cormed (US), Yukon Medical (US), Caragen Ltd. (Ireland), Equishield, and others are among the major participants in the Closed System Drug Transfer Device Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
1 MARKET DYNAMICS
1.1 INTRODUCTION
1.2 DRIVERS
1.2.1 INCREASING INCIDENCES OF CANCER ACROSS THE GLOBE
1.2.2 STRINGENT REGULATORY REQUIREMENTS WITHIN THE HEALTHCARE INDUSTRY
1.3 RESTRAINTS
1.3.1 HIGH COST ASSOCIATED WITH CSTD
1.4 OPPORTUNITY
1.4.1 GROWING TECHNOLOGICAL ADVANCEMENTS IN CLOSED SYSTEM DRUG TRANSFER DEVICES (CSTDS)
2 MARKET FACTOR ANALYSIS
2.1 PORTER’S FIVE FORCES MODEL
2.1.1 THREAT OF NEW ENTRANTS
2.1.2 BARGAINING POWER OF SUPPLIERS
2.1.3 THREAT OF SUBSTITUTES
2.1.4 BARGAINING POWER OF BUYERS
2.1.5 INTENSITY OF RIVALRY
2.2 IMPACT OF COVID-19 ON THE GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET
3 GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET, BY TYPE
3.1 INTRODUCTION
3.2 MEMBRANE-TO-MEMBRANE SYSTEMS
3.3 NEEDLELESS SYSTEM
4 GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET, BY COMPONENT
4.1 INTRODUCTION
4.2 SYRINGE SAFETY DEVICE
4.3 VIAL ACCESS DEVICES
4.4 ACCESSORIES
4.5 BAG/LINE ACCESS DEVICES
5 GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET, BY CLOSING MECHANISM
5.1 INTRODUCTION
5.2 PUSH TO TURN SYSTEM
5.3 COLOR-TO-COLOR ALIGNMENT SYSTEM
5.4 LEUR LOCK SYSTEMS
5.5 CLICK-TO-LOCK
6 GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
6.2 COMPARTMENTALIZE DEVICES
6.3 DIAPHRAGM-BASED DEVICES
6.4 AIR FILTRATION DEVICES
7 GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET, BY END USER
7.1 INTRODUCTION
7.2 HOSPITALS & CLINICS
7.3 SPECIALTY CENTERS
7.4 OTHERS
8 GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICES MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.2.3 MEXICO
8.3 EUROPE
8.3.1 GERMANY
8.3.2 FRANCE
8.3.3 UK
8.3.4 ITALY
8.3.5 SPAIN
8.3.6 REST OF EUROPE
8.4 ASIA-PACIFIC
8.4.1 CHINA
8.4.2 INDIA
8.4.3 JAPAN
8.4.4 SOUTH KOREA
8.4.5 AUSTRALIA
8.4.6 REST OF ASIA-PACIFIC
8.5 REST OF THE WORLD
8.5.1 MIDDLE EAST
8.5.2 AFRICA
8.5.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 MARKET SHARE ANALYSIS, 2023
9.3 COMPETITOR DASHBOARD
9.4 PUBLIC PLAYERS STOCK SUMMARY
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 PRODUCT LAUNCH
9.6.2 PRODUCT APPROVAL
10 COMPANY PROFILES
10.1 B. BRAUN SE
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 JMS CO.LTD.
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIES
10.3 ICU MEDICAL, INC.
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCT OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.3.6 KEY STRATEGIES
10.4 SIMPLIVIA
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIES
10.5 EQUASHIELD
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIES
10.6 BD
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 BAXTER
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 KEY STRATEGIES
10.8 CORMED
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIES
10.9 YUKON MEDICAL
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.9.6 KEY STRATEGIES
10.10 CARAGEN LTD
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
11 DATA CITATIONS